Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18363119 | 0.75 | ALDH1A1 (0.41) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL22015932 | 0.73 | ALDH1A1 (0.34) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL15335166 | 0.73 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL25878496 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL15334892 | 0.71 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL22686382 | 0.71 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL11581015 | 0.68 | KDM4E (0.42) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL8149192 | 0.68 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1USP2LMNA | |
| Nibrozetone SCHEMBL2249018 | 0.67 | NLRP3 (0.47) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL9918122 | 0.64 | APEX1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660286-B2 | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products | EPICENTRX, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11160784-B1 | Treatment of brain metastases using organonitro compound combination therapy | EPICENTRX, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200375982-A1 | TREATMENT OF GLIOMAS USING ORGANONITRO COMPOUND COMBINATION THERAPY | EPICENTRX INC (US) | 2020-12-03 | — | — | US | disclosed |
| US-10543208-B2 | Treatment of gliomas using organonitro compound combination therapy | EPICENTRX, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20200022952-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | EPICENTRX, INC. | 2020-01-23 | — | — | US | disclosed |
| US-20190125742-A1 | TREATMENT OF GLIOMAS USING ORGANONITRO COMPOUND COMBINATION THERAPY | EPICENTRX, INC. | 2019-05-02 | — | — | US | disclosed |
| US-9987270-B1 | Treatment of gliomas using organonitro compound combination therapy | EPICENTRIX, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180085346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | Northrop Grumman Innovation Systems, Inc. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660286-B2 | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products | HBB, HBG2, HBZ | ALDH1A1 1464/4885KDM4E 645/4885MEN1 3834/4885 |
| US-20190125742-A1 | TREATMENT OF GLIOMAS USING ORGANONITRO COMPOUND COMBINATION THERAPY | AQP4, CRYZ, CA5A | ALDH1A1 878/4885KDM4E 1697/4885MEN1 998/4885 |
| US-20200375982-A1 | TREATMENT OF GLIOMAS USING ORGANONITRO COMPOUND COMBINATION THERAPY | AQP4, CRYZ, CA5A | ALDH1A1 878/4885KDM4E 1697/4885MEN1 998/4885 |
| US-20180085346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885KDM4E 2028/4885MEN1 1992/4885 |
| US-20200022952-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | HBB, HBG2, HBZ | ALDH1A1 1464/4885KDM4E 645/4885MEN1 3834/4885 |
| US-10543208-B2 | Treatment of gliomas using organonitro compound combination therapy | AQP4, CRYZ, CA5A | ALDH1A1 878/4885KDM4E 1697/4885MEN1 998/4885 |
| US-11160784-B1 | Treatment of brain metastases using organonitro compound combination therapy | XPO5, CA5A, XPO1 | ALDH1A1 1580/4885KDM4E 2149/4885MEN1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.